In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

Related resources

Full-text held externally

University researcher(s)

    Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

    Bailey, Swneke D; Xie, Changchun; Do, Ron; Montpetit, Alexandre; Diaz, Rafael; Mohan, Viswanathan; Keavney, Bernard; Yusuf, Salim; Gerstein, Hertzel C; Engert, James C; Anand, Sonia;

    Diabetes care. 2010;33(10):2250-3.

    Access to files

    Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

    Full-text held externally

    Abstract

    OBJECTIVE: Thiazolidinediones are used to treat type 2 diabetes. Their use has been associated with peripheral edema and congestive heart failure-outcomes that may have a genetic etiology. RESEARCH DESIGN AND METHODS: We genotyped 4,197 participants of the multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial with a 50k single nucleotide polymorphisms (SNP) array, which captures ∼2000 cardiovascular, inflammatory, and metabolic genes. We tested 32,088 SNPs for an association with edema among Europeans who received rosiglitazone (n = 965). RESULTS: One SNP, rs6123045, in NFATC2 was significantly associated with edema (odds ratio 1.89 [95% CI 1.47-2.42]; P = 5.32 × 10(-7), corrected P = 0.017). Homozygous individuals had the highest edema rate (hazard ratio 2.89, P = 4.22 × 10(-4)) when compared with individuals homozygous for the protective allele, with heterozygous individuals having an intermediate risk. The interaction between the SNP and rosiglitazone for edema was significant (P = 7.68 × 10(-3)). Six SNPs in NFATC2 were significant in both Europeans and Latin Americans (P < 0.05). CONCLUSIONS: Genetic variation at the NFATC2 locus contributes to edema among individuals who receive rosiglitazone.

    Bibliographic metadata

    Type of resource:
    Content type:
    Publication type:
    Published date:
    Journal title:
    Abbreviated journal title:
    ISSN:
    Place of publication:
    United States
    Volume:
    33
    Issue:
    10
    Pagination:
    2250-3
    Digital Object Identifier:
    10.2337/dc10-0452
    Pubmed Identifier:
    20628086
    Pii Identifier:
    dc10-0452
    Access state:
    Active

    Institutional metadata

    University researcher(s):
    Academic department(s):

    Record metadata

    Manchester eScholar ID:
    uk-ac-man-scw:201256
    Created by:
    Price, Caroline
    Created:
    11th July, 2013, 14:29:58
    Last modified by:
    Price, Caroline
    Last modified:
    11th July, 2013, 14:29:58

    Can we help?

    The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.